Clinical Trial Update: The Role of Anifrolumab in Improving Markers of Vascular Risk in Patients With Systemic Lupus Erythematosus (SLE) - IFN-CVD [Phase 2]

View source ↗

Summary

This is a Phase 2 clinical trial assessing whether anifrolumab improves vascular risk markers in systemic lupus erythematosus; the study is currently recruiting…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cardiovascular Disease
• Premature Atherosclerosis
• Systemic Lupus Erythematosus

Drugs mentioned

• Anifrolumab (anifrolumab)

Snippet

Sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | Conditions: Systemic Lupus Erythematosus, Cardiovascular Disease | Phase 2 | Status: RECRUITING